Effect of Apolipoprotein E on the Prognosis of Patients With Intracerebral Hemorrhage

Plain-language summary

This study examined the effect of the ApoE (Apolipoprotein E) gene on the course of disease in patients with intracerebral hemorrhage. Patients were grouped according to their ApoE genotypes determined by CT scan and a blood sample, and the study enrolled people over 18 with imaging-confirmed intracerebral hemorrhage. It was a trial without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

The Affiliated Hospital Of Guizhou Medical University

Intervention

Non-enhanced CT scan、Nuclear Magnetic Resonance (MRI)

Start date

1/1/2020

Estimated completion

12/1/2023

Countries

China

Related genes

Locations

• Guiyang, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Relevant diagnosis of supratentorial ICH was confirmed through unenhanced CT scanning.
* Patients were distinguished based on venous blood collection, with the presence of the ApoE-ε4 (ε2/ε4, ε3/ε4, ε4/ε4) gene (ApoE-ε4 genotype) and patients harboring the ApoE-ε3 (ε3/ε3) gene (non-ApoE-ε4 genotype).

Exclusion Criteria:

* Patients with infratentorial ICH.
* Patients with ApoE-ε2 (ε2/ε2) based on venous blood collections.
* Younger than 18 years of age.
* ICH caused by trauma, anticoagulation therapy, or antiplatelet therapy.
* Patients admitted to the hospital with diseases that might impact inflammatory responses, such as infective meningitis and systemic infections.
* Patients with previous residual neurological deficits following a stroke.
* Patients with combined tumours, severe liver and kidney dysfunction, cardiac insufficiency.